NEW YORK (GenomeWeb News) – Gentel Biosciences today announced a licensing deal with Oregon Health & Science University covering viral antigens for use on its Colony Surveillance Assays.
The deal is for worldwide commercial use, and the addition of the antigens complements Gentel's strategy to grow its product line to support translational research disease models, it said.
The antigens were developed at the molecular virology laboratory at OHSU's Oregon National Primate Research Center. They will be added to Gentel's CSA: Simian Basic panel, which includes six infectious agents monitored in specific pathogen-free primates. The CSA: Simian Expanded panel will include 11 tests — the six from the Basic panel plus five additional infectious agents.
The expanded panel will be launched in the fall and will run on the Madison, Wis.-based firm's Gentel Proteomics Multi-System platform.
"Our main goal is to allow colony managers to get the lowest false positive/negative rates, in hours and at a significantly lower cost," Alex Vodenlich, president and CEO of Gentel, said in a statement. "Our second goal is to offer a broad enough selection of products that we can serve every [non-human primate] colony in the world. Working with OHSU helps us reach these goals."
Financial and other terms of the deal were not disclosed.